project id: TCGA-PRAD; case submitter id: TCGA-EJ-A65E; selected normal wgs: true; source center: 23; state: released; a260 a280 ratio: 1.87; normal tumor genotype snp match: Yes; ribosomal rna 28s 16s ratio: 1.67; rna integrity number: 9.1; age at index: 67; days to birth: -24558; ethnicity: not reported; gender: male; race: black or african american; vital status: Alive; year of birth: 1945; age at diagnosis: 24558; ajcc clinical m: M0; ajcc clinical t: T3b; ajcc pathologic n: N0; ajcc pathologic t: T3b; classification of tumor: not reported; days to diagnosis: 0; days to last follow up: 417.0; icd 10 code: C61; last known disease status: not reported; morphology: 8255/3; primary diagnosis: Adenocarcinoma with mixed subtypes; primary gleason grade: Pattern 4; prior malignancy: no; prior treatment: No; progression or recurrence: not reported; secondary gleason grade: Pattern 3; site of resection or biopsy: Prostate gland; synchronous malignancy: No; tissue or organ of origin: Prostate gland; tumor grade: Not Reported; year of diagnosis: 2012; treatment or therapy: no; alcohol history: Not Reported; is ffpe: false; composition: Not Reported; days to collection: 289; initial weight: 240.0; sample id: 3f84ae9d-45d9-4c66-a383-ef4151e4106a; sample submitter id: TCGA-EJ-A65E-01A; portion id: 4d87562d-07a6-467c-b278-cc584c6e373b; portion submitter id: TCGA-EJ-A65E-01A-11; slide id: 5cca7b30-7494-41fe-952e-67669c017ae1; slide submitter id: TCGA-EJ-A65E-01A-01-TSA; percent lymphocyte infiltration: 1.0; percent monocyte infiltration: 1.0; percent necrosis: 0.0; percent neutrophil infiltration: 0.0; percent normal cells: 25.0; percent stromal cells: 15.0; percent tumor cells: 60.0; percent tumor nuclei: 80.0; section location: TOP;